OncoHost develops PROphet®, a machine learning-based host response profiling platform that analyzes proteomic changes in blood samples to monitor patients' biological response to cancer therapies. The company combines life-science research and advanced machine learning to design personalized strategies aimed at overcoming therapy resistance. Led by CEO Dr. Ofer Sharon and based in Binyamina, Israel, OncoHost uses proprietary proteomic analysis to understand individual patient responses. It is expanding clinical trial sites worldwide and broadening research into additional cancer indications. PROphet® is planned for U.S. commercial launch in the third quarter of 2022. The company recently completed a financing that will fund its multicenter PROPHETIC trial and support the imminent U.S. launch. OncoHost is a clinical-stage precision oncology startup based in Binyamina, Israel, combining life-science research with advanced machine learning to develop personalized cancer-treatment strategies. Its core product, PROphet®, is a machine learning–based Host Response Profiling platform that combines proteomic analysis with AI to predict patient response to immunotherapy and suggest combination strategies to overcome resistance. The company analyzes proteomic changes in patient blood samples to detect signs of resistance in real time, enabling biomarker-guided treatment planning and target discovery for drug development. Clinical trials are underway in melanoma and non-small cell lung cancer (NSCLC) patients, with plans to expand to other indications. The company is led by CEO Ofer Sharon, MD. The recently completed financing will support ongoing clinical trials, opening a U.S.-based affiliate, and preparation for the commercial launch of PROphet® to healthcare providers.

Total raised

$43M

Funding rounds

2

Latest round

Series C

Latest activity

May 2022